NCT01702467View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

October 19, 2012

Primary Completion Date

May 15, 2013

Study Completion Date

May 15, 2013

Conditions

Alzheimer's Disease

Interventions

DRUG

GSK2647544

Capsules containing 0.5mg to 50mg of GSK2647544.

DRUG

Placebo

Matching placebo capsules.

Trial Locations (1)

2031

GSK Investigational Site, Randwick

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01702467 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers | Biotech Hunter | Biotech Hunter